Carmen Hidalgo Tenorio, Sergio Sequera, María J Vivancos, David Vinuesa, Antonio Collado, Ignacio De Los Santos, Patricia Sorni, Noemi Cabello-Clotet, Marta Montero, Carlos Ramos Font, Alberto Terron, M J Galindo, Onofre Martinez, P Ryan, Mohamed Omar-Mohamed, Helena Albendín Iglesias, Rosario Javier, Miguel ÁngelLópez- Ruz, Alberto Romero, Coral García Vallecillos
OBJECTIVE: Multiple strategies have been utilized to reduce the incidence of HIV, including PrEP and rapid antiretroviral therapy initiation. The study objectives were to evaluate the efficacy, safety, satisfaction, treatment adherence, and system retention obtained with rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in naïve patients. METHODS: This phase IV, multicenter, open-label, single-arm, 48-week clinical trial enrolled patients between January 2020 and June 2022...
April 2, 2024: International Journal of Antimicrobial Agents